PFS Cancer Research Results

PFS, progression-free survival: Click to Expand ⟱
Source:
Type:

PFS (progression-free survival) is the time from a defined starting point—usually randomization or treatment initiation—until documented disease progression or death, whichever occurs first



Scientific Papers found: Click to Expand⟱
9134- CC,    Camu camu plus nivolumab/ipilimumab (N/I) as first-line therapy for metastatic renal cell carcinoma (mRCC): A randomized phase I trial
- Trial, RCC, NA
Dose?, GutMicro↑, toxicity↝, PFS↑,
7000- Fuc,    Efficacy of Low-Molecular-Weight Fucoidan as a Supplemental Therapy in Metastatic Colorectal Cancer Patients: A Double-Blind Randomized Controlled Trial
- Trial, CRC, NA
DCR↑, OS∅, PFS∅, ORR∅, AEs∅, QoL∅,
7311- Gos,    Systematic Review of Gossypol/AT-101 in Cancer Clinical Trials
- Review, CLL, NA
Dose↝, toxicity↓, PFS↓, OS↑, Synergy↑, BioAv↑, Bcl-2↓, ROS↑, MOMP↑, Dose↑, Casp3↑, Casp9↑, MMP↑, VEGF↓, APE1/APEX1↓, ChemoSen↑, RadioS↑, toxicity↑, AST↑, ALAT↑,
7482- H2,    Molecular Hydrogen Therapy: Mechanisms, Delivery Methods, Preventive, and Therapeutic Application
- Review, Var, NA - Review, IBD, NA - Review, Stroke, NA - Review, Sepsis, NA - Review, AD, NA
Dose↝, *Inflam↓, *IL1β↓, *IL6↓, *TNF-α↓, *neuroP↑, *mTOR↓, *IL10↑, *TGF-β↑, *Sepsis↓, *NRF2↑, *antiOx↑, *Catalase↑, *SOD↑, *GPx↑, *ROS↓, *HO-1↑, *PI3K↑, *Akt↑, *hepatoP↑, *MPO↓, *cardioP↑, CDK4↓, CDK6↑, CD47↓, PI3K↓, Akt↓, Hif1a↓, selectivity↑, *MMP↑, *ATP↑, *ER Stress↓, *CHOP/DDIT3↓, *Casp12↓, *GRP78/BiP↓, *p38↓, *p‑JNK↓, *LC3‑Ⅱ/LC3‑Ⅰ↑, *p‑eIF2α↓, *ATF4↓, *XBP-1↓, *Imm↑, *IFN-γ↓, *IL4↓, *GranB/GZMB↓, NK cell↑, radioP↑, *CD4+↑, CD8+↑, *Dose↝, *other↑, *Dose↝, *antiPs↑, *BioAv↝, *GutMicro↑, Dose↝, *IBI↑, TumCP↓, TumCI↓, TumCMig↓, CD8+↑, PGC-1α↑, Akt↓, SCD1↓, *MDA↓, Synergy↑, *APP↓, *BACE/β-secretase↓, *Aβ↓, *cognitive↑, *neuroP↑, NP/CIPN↓, *Stroke↓, *NLRP3↓, *ALAT↓, *AST↓, *LPS↓, *hepatoP↑, chemoP↑, *creat↓, *Urea↓, *RenoP↑, *eff↑, Apoptosis↑, XIAP↓, IAP2/BIRC3↓, TumVol↓, MALAT1↓, EZH2↓, miR-124-3p↓, eff↑, ChemoSen↑, *compII↑, *compIII↑, *LDL↓, *Obesity↓, QoL↑, PFS↑, *antiAll↑,
7990- itraC,    A Novel Approach to Reducing Chemoresistance in Advanced Ovarian Cancer: The Effect of Itraconazole-A Single-Institution Randomized Placebo-Controlled Trial
- Trial, Ovarian, NA
Dose↝, DCR↑, PFS↑, CA125↓, P-gp/ABCB1↓, VEGFR2/KDR/Flk1↑, toxicity↓, QoL↑, toxicity↝,
8018- itraC,  Chemo,    Impact of combination chemotherapy with itraconazole on survival of patients with refractory ovarian cancer
- Trial, Ovarian, NA
PFS↑, OS↑, other↝,
8128- LF,    Phase 2 trial of talactoferrin in previously treated patients with metastatic renal cell carcinoma
- Trial, RCC, NA
Imm↑, NK cell↑, Dose↝, toxicity↓, PFS↑,
8126- LF,    Randomized, double-blind, placebo-controlled phase II study of single-agent oral talactoferrin in patients with locally advanced or metastatic non-small-cell lung cancer that progressed after chemotherapy
- Trial, NSCLC, NA
Dose↝, OS↑, PFS↑, DCR↑, other↝,
8631- MBZ,  BEV,    Mebendazole; from an anti-parasitic drug to a promising candidate for drug repurposing in colorectal cancer
- Trial, CRC, NA
Dose?, Synergy↑, PFS↑, VEGF↓, ChemoSen↑,
8795- mCHEMO,    Short-term versus long-term metronomic adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma: A propensity score-matched real-world study
- Trial, NPC, NA
other↝, OS↑, PFS↑, toxicity↝,
8786- mCHEMO,    Metronomic chemotherapy in cancer treatment: new wine in an old bottle
- Review, Var, NA
eff↑, ChemoSideEff↓, angioG↓, *toxicity↓, PFS↑, Hif1a↓, TumCD↑, CSCs↓, EMT↓, Bcl-2↓, BAX↑, Casp3↑, Casp7↑, CD133↓, TumCCA↑, P21↓, DNAdam↑, Imm↑, Synergy↑, Synergy↑,
8791- mCHEMO,    Real-World Efficacy of Metronomic Chemotherapy in Advanced Breast Cancer Across Molecular Subtypes
- Trial, BC, NA
PFS?, OS↑, eff↑,
8792- mCHEMO,    Early capecitabine metronomic chemotherapy improves patient prognosis and safety in early-stage triple-negative breast cancer
- Trial, BC, NA
PFS↑, eff↑,
8707- MET,    Metformin in therapeutic applications in human diseases: its mechanism of action and clinical study
- Review, Var, NA - Review, AD, NA
*BioAv↝, *cardioP↑, *Obesity↓, *neuroP↑, *toxicity↝, *Dose↝, *GutMicro↑, *AMPK↑, *glucose↓, *NLRP3↑, *Inflam↓, *Stroke↓, *Cartilage↑, FOXP3↑, TumAuto↑, mTOR↓, PD-L1↓, RadioS↑, ChemoSen↑, ROS↓, OXPHOS↓, compI↓, Glycolysis↝, TumCP↓, *BioAv↝, *AntiAge↑, *SIRT1↑, *cognitive↑, *Risk↓, Ki-67↓, Synergy↝, PFS∅, OS∅,
8481- MFrot,    Therapeutic Magnetic Fields in Oncology: A Systematic Review of Safety and Supportive Clinical Use
- Review, Var, NA
*toxicity↓, *PFS∅, *ORR∅, *DCR∅, *other↝, *TumCG↓,
7708- NIV,  lpi,    Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial
- Trial, CRC, NA
PFS↑,

Showing Research Papers: 1 to 16 of 16

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 16

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

ROS↓, 1,   ROS↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

compI↓, 1,   OXPHOS↓, 1,   PGC-1α↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ALAT↑, 1,   Glycolysis↝, 1,   SCD1↓, 1,  

Cell Death(tgid=5) ⓘ

Apoptosis↑, 1,   BAX↑, 1,   Bcl-2↓, 2,   Casp3↑, 2,   Casp7↑, 1,   Casp9↑, 1,   IAP2/BIRC3↓, 1,   MOMP↑, 1,   TumCD↑, 1,   XIAP↓, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

Akt↓, 2,   mTOR↓, 1,   PI3K↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

EZH2↓, 1,   miR-124-3p↓, 1,   other↝, 3,  

Autophagy & Lysosomes(tgid=9) ⓘ

TumAuto↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

APE1/APEX1↓, 1,   DNAdam↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK4↓, 1,   CDK6↑, 1,   Ki-67↓, 1,   P21↓, 1,   TumCCA↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

CD133↓, 1,   CSCs↓, 1,   Ki-67↓, 1,   TumCP↓, 2,  

Migration(tgid=13) ⓘ

EMT↓, 1,   MALAT1↓, 1,   TumCI↓, 1,   TumCMig↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 1,   Hif1a↓, 2,   VEGF↓, 2,   VEGFR2/KDR/Flk1↑, 1,  

Barriers & Transport(tgid=15) ⓘ

MMP↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CD47↓, 1,   CD8+↑, 2,   FOXP3↑, 1,   Imm↑, 2,   NK cell↑, 2,   PD-L1↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↑, 1,   ChemoSen↑, 4,   Dose?, 2,   Dose↑, 1,   Dose↝, 6,   eff↑, 4,   P-gp/ABCB1↓, 1,   RadioS↑, 2,   selectivity↑, 1,   Synergy↑, 5,   Synergy↝, 1,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↑, 1,   AST↑, 1,   CA125↓, 1,   EZH2↓, 1,   PD-L1↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AEs∅, 1,   chemoP↑, 1,   ChemoSideEff↓, 1,   DCR↑, 3,   NP/CIPN↓, 1,   ORR∅, 1,   OS↑, 5,   OS∅, 2,   PFS?, 1,   PFS↓, 1,   PFS↑, 11,   PFS∅, 2,   QoL↑, 2,   QoL∅, 1,   radioP↑, 1,   toxicity↓, 3,   toxicity↑, 1,   toxicity↝, 3,   TumVol↓, 1,  

Infection & Microbiome(tgid=24) ⓘ

GutMicro↑, 1,  
Total Targets: 87

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 1,   Catalase↑, 1,   GPx↑, 1,   HO-1↑, 1,   MDA↓, 1,   MPO↓, 1,   NRF2↑, 1,   ROS↓, 1,   SOD↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

compII↑, 1,   compIII↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ALAT↓, 1,   AMPK↑, 1,   ATP↑, 1,   glucose↓, 1,   LDL↓, 1,   SIRT1↑, 1,  

Cell Death(tgid=5) ⓘ

Casp12↓, 1,   GranB/GZMB↓, 1,   p38↓, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

Akt↑, 1,   p‑JNK↓, 1,   mTOR↓, 1,   PI3K↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

ATF4↓, 1,   other↑, 1,   other↝, 1,  

Protein Folding & ER Stress(tgid=8) ⓘ

CHOP/DDIT3↓, 1,   p‑eIF2α↓, 1,   ER Stress↓, 1,   GRP78/BiP↓, 1,   XBP-1↓, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

LC3‑Ⅱ/LC3‑Ⅰ↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

TumCG↓, 1,  

Migration(tgid=13) ⓘ

Cartilage↑, 1,   TGF-β↑, 1,  

Barriers & Transport(tgid=15) ⓘ

IBI↑, 1,   MMP↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CD4+↑, 1,   IFN-γ↓, 1,   IL10↑, 1,   IL1β↓, 1,   IL4↓, 1,   IL6↓, 1,   Imm↑, 1,   Inflam↓, 2,   LPS↓, 1,   NLRP3↓, 1,   NLRP3↑, 1,   TNF-α↓, 1,  

Protein Aggregation(tgid=19) ⓘ

APP↓, 1,   Aβ↓, 1,   BACE/β-secretase↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↝, 3,   Dose↝, 3,   eff↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 1,   AST↓, 1,   creat↓, 1,   IL6↓, 1,   Urea↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiAge↑, 1,   antiAll↑, 1,   antiPs↑, 1,   cardioP↑, 2,   cognitive↑, 2,   DCR∅, 1,   hepatoP↑, 2,   neuroP↑, 3,   Obesity↓, 2,   ORR∅, 1,   PFS∅, 1,   RenoP↑, 1,   Risk↓, 1,   Stroke↓, 2,   toxicity↓, 2,   toxicity↝, 1,  

Infection & Microbiome(tgid=24) ⓘ

GutMicro↑, 2,   Sepsis↓, 1,  
Total Targets: 79

Scientific Paper Hit Count for: PFS, progression-free survival
4 MCT, metronomic chemo
2 itraconazole
2 Lactoferrin/Talactoferrin
1 Camu camu
1 Fucoidan
1 Gossypol/AT-101
1 Hydrogen Gas
1 Chemotherapy
1 mebendazole
1 Bevacizumab (brand Avastin)
1 Metformin
1 Magnetic Field Rotating
1 nivolumab
1 ipilimumab
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:1559  State#:%  Dir#:%
wNotes=0 sortOrder:rid,rpid

 

Home Page